Strategies for physician education in therapeutic drug monitoring

Clinical Chemistry

Volumn 44, Issue 2, 1998, Pages 401-407

  Bates, David W ^a,e   Soldin, Steven J ^b   Rainey, Petrie M ^c   Micelli, Joseph N ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b National Children's Medical Center   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; VANCOMYCIN;

COMPUTER; COMPUTER SYSTEM; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DRUG DETERMINATION; DRUG MONITORING; EDUCATION; EVIDENCE BASED MEDICINE; HUMAN; PHYSICIAN; PHYSICIAN ATTITUDE; QUALITY CONTROL;

EID: 0031884964     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.2.401     Document Type: Conference Paper

References (20)

1. Schoenenberger RA, Tanasijevic MJ, Jha A, Bates DW. Appropriateness of antiepileptic drug level monitoring. JAMA 1995;274:1622-6.
2. Canas F, Tanasijevic M, Ma'Luf N, Bates DW. Evaluating the appropriateness of digoxin level monitoring [Abstract]. J Gen Intern Med 1997;12:66.
3. Guyatt GH, Rennie D. Users' guides to the medical literature [Editorial]. JAMA 1993;270:2096-7.
4. Soumerai SB, Avorn J. Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Milbank Mem Fund Q Health Soc 1984;62:447-74.
5. Harpole LH, Khorasani R, Kuperman G, Fiskio J, Bates DW. On-line counterdetailing: does it change physician behavior when ordering abdominal radiographs? [Abstract]. J Gen Intern Med 1996;11:74.
6. Pearson SD, Goulart-Fisher D, Lee TH. Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med 1995;123:941-8.
7. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993;27:594-8.
8. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43.
9. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994;344:1748-50.
10. Lomas J, Sisk JE, Stocking B. From evidence to practice in the United States, the United Kingdom, and Canada. Milbank Q 1993;71:405-10.
11. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989;321:1306-11.
12. Ried LD, McKenna DA, Horn JR. Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring. Am J Hosp Pharm 1989;46:945-51.
13. Koren G, Soldin SJ, MacLeod SM. Organization and efficacy of a therapeutic drug monitoring consultation service in a pediatric hospital. Ther Drug Monit 1985;7:295-8.
14. Wing D, Duff HJ. Impact of a therapeutic drug monitoring program for digoxin. Arch Intern Med 1987;147:1405-8.
15. Tonkin AL, Bochner F. Therapeutic drug monitoring and outcome. Clin Pharmacokinet 1994;27:169-74.
16. Sittig DF, Stead WW. Computer-based physician order entry: the state of the art. J Am Med Inform Assoc 1994;1:108-23.
17. Bates DW, Kuperman G, Teich JM. Computerized physician order entry and quality of care. Qual Manag Health Care 1994;2:18-27.
18. Tierney WM, Miller ME, Overhage JM, McDonald CJ. Physician inpatient order writing on microcomputer workstations. Effects on resource utilization. JAMA 1993;269:379-83.
19. Bates DW, O'Neil AC, Boyle D, Teich J, Chertow GM, Komaroff AL, Brennan TA. Potential identifiability and preventability of adverse events using information systems. J Am Med Inform Assoc 1994;1:404-11.
20. Harrison JH Jr, Rainey PM. Identification of patients for pharmacologic review by computer analysis of clinical laboratory drug concentration data. Am J Clin Pathol 1995;103:710-7.